Probi to launch Probi Digestis® in Turkey

Probi has signed a distribution agreement with Impexia, a pharmaceutical sales
and marketing company well established in the Turkish market. Impexia plans to
launch Probi Digestis® during Q3, 2014.

Turkey is a fast moving economy and has a growing probiotic market with several
new players succesfully launching new probiotic products lately. The market is
expanding and new brands are growing as the medical community is increasing its
appreciation for probiotics.

“Impexia is committed  to gain market share in the years to come” says Peter
Nählstedt, CEO of  Probi. Mr. Nählstedt adds, “Impexia is a strong Partner of
Probi’s with good market access to key geografical areas in Turkey having high
potential for Probi Digestis®. Probi Digestis®has a large number of positive
clinical studies within gut health such as reduction or elimination of symptoms
associated with Irritable Bowel Syndrome”.

Probi Digestis® is based on Lactobacillus plantarum 299v, which targets
bloating, gas formation and pain, common symptoms that are sometimes mild or
temporary but often more severe and causing a low quality of life for people
suffering from such symptoms.

“Probi Digestis® will be launched under the Probi brand in Turkey to emphasize
the high quality probiotic ingredient, invented and further developed by Probi”
says Tayfun Kapcioglu, COO of Impexia, adding: ”Probi Digestis® will be sold via
Impexia’s field force targeting GPs and Gastroenterologists and the large number
of pharmacies available in the Turkish market”.

“Probi is looking forward to entering the Turkish market  and we will be
supporting this key launch through high involvement in the marketing
activities”, says Peter Nählstedt. “We are very much looking forward to a
productive cooperation with Impexia in Turkey”

The information is such that Probi AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

FOR FURTHER INFORMATION, CONTACT:
Peter Nählstedt, CEO, Probi, phone +46 46 286 89 23 or mobile +46 723 86 99
83, e-mail: Peter.Nahlstedt@probi.se
Niklas Bjärum, Vice President Marketing & Sales, Probi, phone +46 46 286 89 67
or mobile +46 705 38 88 64, e-mail: Niklas.Bjarum@probi.se

ABOUT PROBI
Probi AB is a Swedish publicly traded biotechnology company that develops
effective and well-documented probiotics. Through its research, Probi has
created a strong product portfolio in the gastrointestinal health and immune
system areas. The products are available to consumers in more than 30 countries
worldwide. The customers are leading food, health-product and pharmaceutical
companies in the Functional Food and Consumer Healthcare segments. Probi had
sales of MSEK 102 in 2013. The Probi share is listed on NASDAQ OMX Stockholm,
Small-cap. Probi has approximately 3,500 shareholders. Read more on
www.probi.se.

ABOUT IMPEXIA
Impexia is a pharmaceutical sales and marketing company with import from Europe
(medical diagnostics) and USA (derma-cosmetics). Impexia supply more than 5,000
pharmacies throughout Turkey and has strong media connections providing a unique
ability for promotion and branding.